Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

Dr. Rugo details her management strategy in regards to GI toxicities.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

What specific strategies do you use for mitigating gastrointestinal toxicities associated with abemaciclib in the adjuvant setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Close-Up of Female Doctor Analyzing Digital Mammogram on Touchscreen with Stylus. | Image Credit: spyrakot - stock.adobe.com.jpeg

AI in Breast Cancer Care Outpaces Coverage and Guidelines

ByElla Hohmann, MS

July 21st 2026

FDA approved - wladimir1804 - AdobeStock_408414612.jpeg

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

ByGiuliana Grossi

July 15th 2026

Dr Jennifer Sheng | Image Credit: Johns Hopkins Medicine

Multidisciplinary Collaboration Advances Breast Cancer Care: Jennifer Sheng, MD

BySabrina McCrear,Jennifer Sheng, MD

July 10th 2026

Dr Jennifer Sheng | Image Credit: Johns Hopkins Medicine

Consistent Follow-Up Strengthens Breast Cancer Survivorship Care: Jennifer Sheng, MD

BySabrina McCrear,Jennifer Sheng, MD

July 9th 2026

Sudha Rao, PhD, became chief scientific officer for Kazia Therapeutics in April 2026.

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

July 2nd 2026

Trending on AJMC

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog

PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women

CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited

Geographical Access to Preferred Pharmacies in Medicare Part D